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Abstract
Epilepsy is one of the most common neurological diseases, affecting approximately 1%
of the population. It is a chronic disease and increased incidence falls in the period up
to 1 year and 65 years of age. Most patients require long-term antiepileptic drugs (AEDs)
therapy.  In  addition,  approximately  30%  of  patients  with  epilepsy  do  not  obtain
satisfactory seizure control, which is defined as drug-resistant epilepsy. It is postulated
that one of the causes of drug resistance can be polymorphisms of ABCB1/MDR1 gene,
tested particularly in tumors. It is believed that the old generation of AEDs, e.g. CBZ,
VPA, may change plasma Hcy, asymmetric dimethylarginine (ADMA) levels, disturb
lipid levels, C-reactive protein, vitamins, markers of oxidative stress, which are risk
factors for vascular and neurodegenerative diseases. Changes in the level of risk factors
for vascular disease caused by enzymes inducing AEDs, CBZ, PB, and PHT lead to a
small increase in the risk of myocardial infarction. Alteration of Hcy and ADMA levels
are also linked to genetic factors, e.g. genetic variants of MTHFR, MTR, MTHFD1, CBS,
DDAH1, eNOS genes. Individualization of treatment with AEDs and prevention against
cardiovascular disease in patients with epilepsy may bring the best therapeutic effects
in these patients.
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1. Introduction
Epilepsy is one of the most common neurological diseases. It is estimated that approximately
50 million people worldwide suffer from epilepsy. The most common treatment of epilepsy is
based on long-term use of antiepileptic drugs (AEDs).
AEDs are a very heterogeneous group and exhibit different mechanisms of action. It is divided
broadly into two generations: older and newer AEDs. It is believed that the new AEDs are
characterized by greater specificity of the mechanism of action, a proper clinical assessment
of the first trial and less side effects. New generation (NG) drugs are also rarely caused
interactions with other drugs and lesser extent affect mood and cognitive function. On the
other hand, the old AEDs should be applied carefully with consideration of drug interactions
and potential side effects, e.g., increase homocysteine (Hcy) level [1].
Currently, many studies on hyperhomocysteinemia (HHcy) in epileptic patients treated with
AEDs have been performed. The literature indicates that carbamazepine (CBZ) therapy in
epileptics leads to an increase of Hcy [2–5]. Treatment with valproic acid (VPA), however, has
variable effects; in some cases, Hcy is decreased [6], in others, it is increased [2–4, 7, 8], and in
yet others, VPA has no effect on Hcy levels [9–11]. However, lamotrigine (LTG) treatment of
epileptic patients has not been shown to lead to an increase in Hcy [6, 12].
It is believed that AEDs increase Hcy level by lowering the level of folate (FA), cofactor
remethylation of Hcy to methionine, as a result of impaired the intestinal absorption, increased
demand of FA for the hydroxylation processes of AEDs, the activation of hepatic enzymes
leading to a final reduction of the FA level or AEDs direct effect on the metabolism of Hcy and
renal function [13]. It is believed that only CBZ, phenytoin (PHT), phenobarbital (PB) and
primidone reduce the level of FA by an increased activity of liver enzymes [3, 10]. However,
VPA does not induce hepatic microsomal enzyme, but may lead to a decrease [2], as well as
an increase [3] in the FA level. The VPA may reduce the FA level by inhibiting the enzyme
intermediate in biosynthesis of FA and its derivatives. It has been shown that VPA is indeed
associated with a lower risk of deficit of FA.
Elevated concentrations of Hcy in epileptic patients treated with AEDs may be associated with
a number of clinical complications. It has been shown that increased Hcy level may lead to
vascular disease [14], neuropsychiatric [13] and is considered to be a risk factor for seizure and
resistance to treatment with AEDs [15].
Literature data have shown that there is a link between HHcy and asymmetric dimethylargi-
nine (ADMA) level in epilepsy [16, 17]. ADMA is considered to be a risk factor for cardiovas-
cular disease [18]. It has been shown that ADMA may mediate atherogenic action of Hcy [14].
ADMA levels in the plasma of patients with atherosclerosis correlate with both endothelial
dysfunction and the progression of atherosclerosis [19, 20]. ADMA is a known marker of
atherosclerosis [21, 22].
Recent data have also shown that epilepsy patient treated with AEDs may exhibit increased
risk of the myocardial infarction, stroke and cardiovascular death [23, 24]. This may be
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triggered by influencing the serum Hcy and ADMA concentration [16], the serum lipid levels
[25], C-reactive protein (CRP), body weight, as well as other atherosclerotic factors by AEDs [1].
2. Epilepsy and antiepileptic drugs
Epilepsy is not a disease in itself but rather a collection of somatic, vegetative or mental
symptoms, which may be the result of a morphological or metabolic change in the brain. The
etiology of the disease is varied, and among the most common causes are genetic factors, head
trauma, tumors, as well as vascular, degenerative, demyelinating, inflammatory and toxic
brain diseases. However, in 60% of the patients the causes of the illness remain still unknown.
Traditionally, the patient could have been diagnosed of epilepsy after at least two unprovoked
seizures occurring greater than 24 h apart. It has changed recently when the International
League Against Epilepsy (ILAE) established the new operational (practical) clinical definition.
In some cases these new criteria enable the doctors to speed up the diagnosis and apply the
AEDs even after first seizure, when there is a high probability of having another attack [26].
AEDs are among the most common medications used in neurology. Nevertheless, treatment
of epilepsy despite over 20 antiseizure drugs is still a challenge, even for an experienced
neurologist/epileptologist. Unfortunately, the seizure control in almost 20–40% of the patients
remains unsatisfactory. The reasons for refractory epilepsy are not fully clear, however, some
literature data have shown that polymorphisms of a few genes, e.g., ABCB1/MDR1 may
influence the good or poor therapeutic response [27, 28].
The older generation of AEDs consists of CBZ, VPA, PHT, PB, ethosuximide (ESM) and
benzodiazepines (BZDs). The new generation (NG) include LTG, topiramate (TPM), gabapen-
tin (GBP), oxcarbazepine (OXCBZ), levetiracetam (LEV), pregabalin (PGB), tiagabine (TGB),
vigabatrin (VGB), lacosamide (LCM), and perampanel (PMP). Very important characteristic
of AEDs is their ability to induce liver cytochrome P450 (CBZ, PHT, PB) or to block its activity
(VPA), which plays an essential role in drug interactions [16, 29]. AEDs act against different
targets and have distinguishing pharmacokinetics, efficacy, tolerability and side effects [30].
Although for some AEDs the precise mechanism of action remains still unknown and most of
them seem to exhibit more than one mechanism, especially VPA, TPM, and PB, they may be
categorized by their principal goal. CBZ, PHE, LTG, OXCBZ, and ZNS act by blocking the
activity of voltage-gated sodium channels, while ESM, GBP and PG modulate calcium ones
[31]. Increase in gamma-aminobutyric (GABA)ergic transmission by affecting GABAA
receptors, GABA synthesis reuptake or degradation is known for VGB, TGB and BDP.
Inhibition of glutamatergic excitation is distinctive for one of the newest drug—PMP [32].
Another mechanism of action is selectively enhancing slow inactivation of voltage-gated
sodium channels which has been proved for LCM. Finally, LEV and BRV have an ability to
bind to synaptic vesicle SV2A protein [33].
It is known that the use of AEDs, especially for many years induces many adverse effects. The
most common side effects of AEDs are sedation, dizziness, ataxia, headache, joint pain, fever,
vomiting, eating disorders, clotting disorders, hair loss, gingival hyperplasia, and allergic
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reactions [29]. It is believed that the AEDs in pregnant women with epilepsy are the most
common causes of fetal defects [34, 35].
3. Polymorphism of the ABCB1/MDR1 genes and antiepileptic drugs
The ABCB1/MDR1 gene encodes the P-glycoprotein (P-gp), a transmembrane transporter
located at the endothelial cells of the blood-brain barrier (BBB). It is known that overexpression
of P-gp by reducing concentration of AEDs in affected brain regions is associated with epilepsy
pharmacoresistance. The ABCB1/MDR1 gene is highly polymorphic therefore it has great
variability in the level of P-gp expression and activity among epileptic patients [36]. It is
postulated that one of the causes of losing effectiveness of epilepsy treatment may be just
polymorphisms of this gene, which has been mostly studied in the context of drug resistant in
human cancer cells. There have been described three single nucleotide polymorphisms in the
ABCB1/MDR1 gene C3435T, C1236T and G2677 (A/T) related to epilepsy.
The first, ABCB1/MDR1 C3435T is located in exon 26. It has been showed that patients with
drug-resistant epilepsy were more likely to have the CC than the TT genotype and it is
associated with increased expression of the protein that influences the response to AED
treatment [37]. These results have not been confirmed by other studies conducted in Indian
population [38].
Moreover, the literature data indicate that there is an association between C3435T polymor-
phism and CBZ doses. The study of Sterjev et al. [39] indicated that patients with the TT
genotype require a higher dose of CBZ in comparison with patients with the CT and CC
genotypes. No differences in allele frequency and genotype distribution between patient
resistance and response on CBZ were observed. Nevertheless, the authors suggest that the
genetic variant is not the major responsiveness factor to CBZ treatment. However, in the case
of the other hepatic enzyme-inducing AEDs, PB, Basic et al. [40] showed that epileptic patients
with CC homozygote had a significantly lower concentration of PB in the cerebrospinal fluid
(CSF) than CT heterozygotes and TT homozygotes and they have had also reduced penetration
of PB into the brain. Moreover, these patients had a higher seizure frequency than the others.
The other polymorphisms of ABCB1/MDR1 C1236T and G2677 (A/T) are located in 12 and 21
exons, respectively. It has been showed that both and C3435T polymorphisms have an
influence on the AEDs treatment and may be useful in predicting drug-resistant epilepsy [41].
However, the study of Haerian et al. [42] did not demonstrate association between C1236T,
C3435T, and G2677 (A/T) and response to VPA treatment in patient with epilepsy. It was found
that there were no differences regarding G2677 (A/T) genotype in CSF concentration of PB [40].
It was also showed that there was no correlation with seizure frequency [27].
The literature data did not indicate an important role of ABCB1/MDR1 gene polymorphisms
in epilepsy treatment. There is still not clear influence on P-gp expression and function in
response to AED therapy. It seems that more precise knowledge of the frequency of ABCB1/
MDR1 polymorphisms may contribute to a better understanding of disease pathomechanism
and its implications for the effective treatment.
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4. Genes important for homocysteine and ADMA metabolism and
antiepileptic drug therapy in epilepsy
The polymorphisms in genes MTHFR, MTR, MTHFD1, and CBS involved in Hcy metabolism,
as shown in Figure 1, are not unique to epilepsy and are also involved in heart diseases, neural
tube defects, migraine, stroke, Parkinson’s and Alzheimer’s diseases, schizophrenia, and a few
other disorders [43–45].
Figure 1. Genes associated with homocysteine (Hcy) and asymmetric dimethylarginine (ADMA) metabolism.
MTHFR gene encodes methylenetetrahydrofolate reductase, MTHFR enzyme. The most
common polymorphisms of this gene, C677T and A1298C, are associated with this enzyme
deficiency. The MTHFR C677T polymorphism leads to the substitution of alanine for valine
within the N-terminal catalytic domain of the enzyme. The mean activity of MTHFR enzyme
in individuals carrying the CT genotype is 65%, while in TT variant carriers it reaches only
30%, both in comparison to the CC genotype. The MTHFR C677T TT is a cause of HHcy [46,
47]. Recent meta-analysis has shown that MTHFR C677T polymorphism is a risk factor for
epilepsy [45]. The relation between C677T variants and HHcy in patients with epilepsy treated
with AEDs was widely studied, but the results are ambiguous. The elevated Hcy level was
observed among adult patients with CT and TT genotype [16, 48]. Moreover, it has been shown
that children and young adults with TT genotype treated with AEDs have higher Hcy level
and lower IQ score compared to those with CC genotype [49]. No contribution in HHcy was
found in children treated with CBZ or VPA [50].
The MTHFR A1298C polymorphism leads to the substitution of glutamate for alanine within
the C-terminal regulatory domain of the MTHFR enzyme. The mean activity of MTHFR protein
in subjects with AC genotype is 70%. Furthermore, double heterozygotes of mentioned
polymorphism in MTHFR (CT and AC) have an additional loss of activity [43]. Also the
frequency of diplotype CT677/AC1298 was higher in epileptic patients than in controls and
could be a risk factor for HHcy [51]. The effect of only A1298C polymorphism on Hcy level is
minimal [43, 52]. According to meta-analysis the influence of MTHFR A1298C polymorphism
on epilepsy remains inconsistent [45].
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MTR gene encodes methionine synthase, MTR enzyme, while MTRR encodes methionine
synthase reductase, MTRR enzyme. MTRR protein catalyzes the conversion of inactive form
of MTR into active. Both enzymes, MTR and MTRR, are essential for Hcy remethylation to
methionine. MTR A2756G polymorphism converts aspartic acid to glycine and in MTRR A66G
methionine replaces isoleucine. It was observed that MTR A2756G and MTRR A66G poly-
morphisms are associated with increased Hcy level due to reduction in enzyme activity and
may be risk factors for HHcy [53, 54]. On the other hand, other studies deny the influence of
G allele of MTR A2756G on Hcy level, also in epileptic patients [16, 55]. The G allele of this
polymorphism occurred more frequent in epileptics than in controls [16].
MTHFD1 gene encodes three-functional enzyme methylenetetrahydrofolate dehydrogenase/
methyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase, MTHFD1 that
regulates the Hcy circulation. MTHFD1 G1958A polymorphism results in the substitution of
an arginine by a glutamine. According to Sniezawska et al. [16], the AA genotype was more
frequent in epileptic patients than in controls, but only wild-type genotype was associated
with increased Hcy level in AED-treated patients.
CBS gene encodes cystathionine beta-synthase, CBS, an enzyme responsible for Hcy degra-
dation to cystathionine. Missense mutation in CBS gene leads to its deficiency and homocys-
tinuria. Reversible cerebral white matter lesions were found in MRI among patients with CBS
deficiency [56]. CBS T833C polymorphism results in substitution of threonine for isoleucine.
Another widely studied polymorphism is 844ins68. The T833C/844ins68 polymorphism is
associated with mild HHcy [57]. However, CBS T833C polymorphism increases the risk of
HHcy in patients treated with AEDs. Moreover, among 20% of patients with TC genotype and
increased level of Hcy, the seizures were observed [13].
What is interesting, polymorphisms in Hcy metabolism genes also influence the ADMA level.
It was demonstrated that epileptic patients treated with AEDs with gene polymorphisms
MTHFR (C677T), MTR (A2756G), and MTHFD1 (G1958A) had increased level of ADMA [16].
DDAH1 gene encodes dimethylarginine dimethylaminohydrolase, DDAH enzyme that
degrades ADMA, as shown in Figure 1. Isoform 1 of DDAH is highly expressed in brain. Lind
et al. [58] showed that several polymorphisms in DDAH1 gene are related to ADMA level, but
not to endothelium-dependent vasodilatation. Another group identified 4-nucleotide deletion/
insertion variant in the promoter region that leads to reduction of DDAH1 transcription activity
and mRNA level, which increase the ADMA concentration and is a risk factor for thrombosis
stroke and coronary heart disease [59]. Polymorphisms in DDAH1 gene have not been studied
in epilepsy yet.
eNOS gene encodes endothelial isoform of nitric oxide synthase, an enzyme that can be
inhibited by ADMA. It was observed that polymorphisms in eNOS can influence the ADMA
level. Studies performed on rats with pilocarpine-induced status epileptics indicated that
increased eNOS are related with DDAH1 overexpression via augmented ADMA inhibition
[60]. Overexpression of DDAH1 protects against HHcy-induced cerebral vascular dysfunc-
tion [61]. The possible role for ADMA-DDAH pathway in neuronal activity modulation was
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proposed due to increased ADMA concentration and DDAH1 expression in brain and spinal
cord [62].
5. Antiepileptic drugs and other risk factors of vascular diseases
In the literature, there have been many publications indicating an increase in the plasma Hcy
level in patients with epilepsy treated with AEDs [16, 63]. It has been showed that elevated
level of Hcy above 15 μM (HHcy) in epileptic patients treated with AEDs may be associated
with a number of clinical complications. Older publications indicate that HHcy may lead to
three times increase the risk of myocardial infarction and twice increase the risk of stenosis of
the coronary artery [64] and development of vascular disease [65, 66], neuropsychiatric [13]
and considered a risk factor in seizure resistance and resistance to AEDs treatment [15].
Currently, it is believed that the impact of the AED risk of vascular disease depends on the
type of drug used in patients with epilepsy. AEDs can be divided into two groups: hepatic
enzyme-inducing AEDs (CBZ, PB, PHT) leading to an increase in cholesterol, low-density
lipoprotein (LDL), total cholesterol, triglycerides, C-reactive protein (CRP), and Hcy level and
hepatic enzyme-inhibiting AEDs (VPA) whose impact on the level of Hcy is not clear [16, 24,
67]. It is believed that the action of liver cytochrome P450-inducing AEDs leads to metabolic
changes of macromolecular compounds, in particular lipids [68]. On the other hand, the liver
cytochrome P450 inhibition of AEDs is not associated with metabolic changes but exhibits a
proatherogenic effect by the impact on insulin resistance, body weight gain, and elevated
oxidative stress [69]. At the same time, the share of inducing- and inhibiting AEDs in the
pathogenesis of ischemic stroke and myocardial infarction is diverse.
Although, the study on a cohort of 252,407 patients aged above 18 years of age using inducing
and inhibiting liver enzyme AEDs has shown that inducing AEDs do not lead to an increased
risk of ischemic stroke and cause a small increase in myocardial infarction. While inhibiting
AEDs also do not lead to an increased risk of ischemic stroke and lead to a reduction in the
risk of myocardial infarction [24]. Moreover, according to Renoux et al. [24], only prolonged
use of inducing AEDs led to an increase in the risk of myocardial infarction.
So far there is no effective therapy leading to a reduction in the level of Hcy and/or ADMA
and other risk factors for vascular lesions, e.g., lipids and proteins following the AEDs used
in epilepsy treatment. These issues require further study.
6. Summary
AEDs especially the older generation, including CBZ, PB, and PHT may lead to increased
plasma Hcy concentrations and changes in the level of plasma ADMA in patients with epilepsy,
as shown in Figure 2. It is believed that CBZ, PB, and PHT lead to elevated levels of plasma
Hcy and/or ADMA by inducing liver enzyme. On the other hand, VPA does not lead to
activation of liver enzymes, and its effect on plasma levels of Hcy and/or ADMA is varied.
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Longer duration of the use of AEDs associated with impaired intestinal absorption of FA (CBZ,
PB, and PHT) leads to an increase in incidents of myocardial infarction involving elevated
levels of Hcy and/or ADMA or by other mechanisms of vascular lesions. However, VPA does
not lead to an increase in incidents of ischemic stroke and leads to a decrease of myocardial
infarction. It seems that the toxic effect of AEDs not only involves production of neurotoxic
Hcy but also involves induction of apoptosis.
Figure 2. Antiepileptic drugs (AEDs) and risk factors of vascular diseases in epilepsy. Enzymes associated with Hcy-
homocysteine metabolism, MTHFR, MTR, MTHFD1. ADMA, asymmetric dimethylarginine; CBZ, carbamazepine;
VPA, valproic acid; PHT, phenytoin; PB, phenobarbital; ↑, increase; ↓, decrease level.
Supplementation with B-group vitamins and FA, and arginine may improve the effectiveness
of AED therapy in patients with epilepsy.
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